Retinal Drugs Market Summary
As per Market Research Future Analysis, the Retinal Drugs Market was valued at 6.17 USD Billion in 2024 and is projected to grow to 11.36 USD Billion by 2034, with a CAGR of 6.30% from 2025 to 2034. The market is driven by the increasing prevalence of retinal diseases, a growing geriatric population, and rising diabetes incidence globally. The demand for sustained-release ocular formulations is also on the rise, addressing the challenges of current treatment methods.
Key Market Trends & Highlights
The market is witnessing significant trends that are shaping its growth trajectory.
- The prevalence of retinal diseases is increasing, with AMD expected to affect 202 million people globally.
- Hospital pharmacies dominated the market in 2022, reflecting their critical role in treatment.
- Macular degeneration held the largest market share in 2022, driven by regulatory support and increasing incidence.
- The Asia-Pacific region is expected to register the fastest CAGR from 2023 to 2032, due to rising diabetes rates.
Market Size & Forecast
2024 Market Size | USD 6.17 Billion |
2034 Market Size | USD 11.36 Billion |
CAGR (2025-2034) | 6.30% |
Major Players
Key players include Bayer AG, Alcon Inc., Alimera Sciences Inc., Bausch Health Co Inc., Bristol Myers Squibb Co., Hoffmann La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc.